Increasing number of trauma and surgical procedures where only hemostatic agents can be used to manage bleeding is expected to drive the global topical hemostats market near the future. Topical absorbable hemostats including collagen, polysaccharide, gelatin, oxidized regenerated cellulose and combination hemostats comprises of an absorbable sponge, foam, pad and other material with a topical hemostatic agent used to apply on bleeding site. These products also used in surgical specialty procedures.
The Market of Topical Absorbable Hemostats is projected to witness lucrative growth over the forecast period owing to increase in demand supported by rising surgery volumes. Additionally, increasing prevalence of chronic conditions and increasing geriatric population are driving the growth of market. For instance, according to Centers for Disease Control and Prevention (CDC) statistics, more than 45% of American population suffers from at least one chronic condition requiring critical care. Moreover, companies are investing on research and development expected to fuel the growth of market. For instance, Ethicon, LLC has ongoing clinical trial intended to study for surgical powder moderate parenchymal or soft tissue intraoperative bleeding.
The Global Topical Absorbable Hemostats market is segmented on the basis of product and region. Based on the products, the market is divided into combination hemostats – pads, oxidized regenerated cellulose-based hemostats, polysaccharide-based hemostats, gelatin-based hemostats, collagen-based hemostats and others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of forecast period.
The key players of this market include 3-D Matrix Ltd, Angiotech Pharmaceuticals Inc, Anika Therapeutics Inc, APRUS Bio-Medical Innovations Pvt Ltd, Arch Therapeutics Inc, Baxter, C.R. Bard, Cellphire Inc, Covalon Technologies Ltd, Cresilon Inc, Endomedix Incorporated, Entegrion Inc, Ethicon, ETX Pharma Inc, Gamma Therapeutics Inc, GATT Technologies BV, gel-e Inc, Gelita, Haemostatix Ltd, Hemostasis LLC, HLL Lifecare Ltd, Keratin Biosciences Inc, Leader Biomedical Europe BV, LifeBond Ltd, Mallinckrodt Pharmaceuticals, Mochida Pharmaceutical Co., Ltd., Pfizer, Protege Biomedical, Resorba GmbH, Sanara MedTech Inc, Sanofi Biosurgery Inc, Sea Run Holdings Inc, Teleflex, Therus Corporation, Thrombotargets Corp, United Health Products, Inc., Xcede Technologies Inc, Z-Medica llc and Integra LifeSciences.